Botanical species · safety record

Bauhinia variegata

The EFSA Compendium of Botanicals holds 8 constituent measurements and 1 adverse-effect record for Bauhinia variegata. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Bauhinia variegata L.

8Constituent measurements
1Safety records
5Cited sources
6Licensed products (Canada)

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 6 licensed products naming Bauhinia variegata as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

  • Dry

Source material stated

  • Aged bark
  • Bark
  • Bark extract
  • Stem bark
  • Whole plant

What the records describe

Constituents measured

  • Alkaloids1
  • Calcium oxalate1
  • Camphor1
  • Cardiac glycosides1
  • Myrcene1
  • Saponins1
  • Tannins1
  • Trypsin inhibitors1

Plant parts

  • Leaves5
  • Flower2
  • Bark1
  • Seed1

Preparations

  • Solvent extraction5
  • Essential oil2
  • Powder1

Effect types

  • Other toxicities1

Target tissues

  • Blood coagulation1

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

SubstancePlant partPreparationConcentrationAnalytical methodSource
CamphorFlowerEssential oil0.7 PercentGC-MSResolve DOI
MyrceneFlowerEssential oil0.4 Gram/100 gramGC-MSResolve DOI
AlkaloidsLeavesSolvent extractionNo resolvable identifier
Calcium oxalateLeavesNo resolvable identifier
Cardiac glycosidesLeavesSolvent extractionNo resolvable identifier
SaponinsLeavesSolvent extractionNo resolvable identifier
TanninsLeavesSolvent extraction5.6 PercentNo resolvable identifier
Trypsin inhibitorsSeedSolvent extractionStandard Chromatographic tests (paper- thin layer- and column chromatography)No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

EffectTarget tissuePlant partPreparationTest organismTest typeSource
Other toxicitiesBlood coagulationBarkPowderRat (as animal)SubchronicNo resolvable identifier

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

  1. Gupta, Rajesh., Paarakh, Padmaa M., Gavani, Usha. Pharmacognostical and phytochemical screening of Bauhinia variegata Linn leaves.. Journal of Pharmacy Research, 2009, vol. 2, no. 7, p. 1196-1198.
  2. Sahoo, Deeptanjali., Ahmad, Ateeque., Ahmad, Jamil., Tandon, Sudeep. Chemical Composition of the Essential oil from Flowers of Bauhinia Variegata (Kachnar) of Northern India. JOURNAL OF ESSENTIAL OIL BEARING PLANTS, 2013, vol. 16, no. 5, p. 636-640. DOI
  3. Di Ciero, L., Oliva, MLV., Torquato, R., Kohler, P., Weder, JKP., Novello, JC., Sampaio, CAM., Oliveira, B., Marangoni, S. The complete amino acid sequence of a trypsin inhibitor from Bauhinia variegata var. candida seeds . Journal of protein chemistry, 1998, vol. 17, no. 8, p. 827-834.
  4. Kolhe, R., Acharya, R.N., Ashok, B.K., Ravishankar, B. Chronic toxicity study of stem bark powder of Kanchanara (Bauhinia variegata L.) in albino rats. Indian journal of natural products and resources, 2014, vol. 5, no. 3, p. 244-248.
  5. Osuga, IM., Abdulrazak, SA., Ichinohe, T., Fujihara, T. Chemical composition, degradation characteristics and effect of tannin on digestibility of some browse species from Kenya harvested during the wet season . Asian-australasian journal of animal sciences, 2005, vol. 18, no. 1, p. 54-60.

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue